DNA-level interventions and the epigenetic landscape underneath aging: gene therapy, CRISPR-based editing, mRNA technology beyond vaccines, and the inherited and acquired patterns that shape longevity trajectories.
Methylation controls over one billion cellular reactions per second, affecting everything from energy to mood to aging. Understanding your unique methylation genetics could be the missing piece in your optimization journey.
Your cells might be aging faster than your calendar. New epigenetic tests decode DNA methylation patterns across 900,000+ markers to reveal your true biological age—even pinpointing which organs age fastest.
Discover how epigenetic testing reveals your true biological age versus chronological age with Ryan Smith, founder of TruDiagnostic. Learn how DNA methylation patterns can predict health outcomes with 92% accuracy and track the effectiveness of longevity interventions in real-time. Smith reveals how aging is the #1 risk factor for chronic disease—10x more significant than smoking or obesity—and demonstrates how epigenetic clocks can measure biological aging from a single drop of blood, providing over 100 biomarkers to optimize your health span.
APOE genotype influences cholesterol transport, neurodegeneration risk, and cardiovascular outcomes. Learn how each allele affects longevity and what to do about it.
CRISPR is the gene editing tool that allows precise changes to DNA. Learn how it works, its longevity applications, current clinical status, and open questions.
Direct-to-consumer genetic testing uses saliva samples to scan your DNA for ancestry, traits, and health risk variants, with real limits on clinical utility.
DNA methylation adds chemical tags to genes that control their activity without changing the DNA sequence, shaping aging, disease risk, and biological age.
Epigenetic age tests use DNA methylation patterns to estimate biological age. This page covers how Horvath, GrimAge, and PhenoAge clocks work and what the evidence shows.
FOXO3 longevity variants are genetic polymorphisms linked to extended lifespan across multiple populations, influencing stress resistance, autophagy, and DNA repair.
Gene therapy introduces, alters, or replaces genetic material to treat or prevent disease. Here is how it works, where the evidence stands, and what it means for aging.
Histone modification controls which genes are active by altering chromatin structure, shaping aging, inflammation, and cellular identity without changing DNA sequence.
The Klotho KL-VS variant is a genetic polymorphism linked to cognition, kidney function, and lifespan, with one copy conferring measurable biological advantages.
mRNA technology instructs cells to produce therapeutic proteins on demand, with applications in cancer, rare disease, and aging biology far beyond vaccines.
MTHFR variants reduce the enzyme that converts folate into its active form, affecting methylation, homocysteine levels, and detoxification capacity.
Polygenic risk scores aggregate thousands of genetic variants into a single estimate of disease susceptibility, informing prevention strategies for longevity.
APOE2, a genetic variant associated with exceptional longevity, activates DNA repair pathways and resists cellular senescence in neurons, while APOE4 exhibits elevated DNA damage and senescence markers. This mechanism extends beyond lipid metabolism, explaining APOE2's protective effects against neurodegeneration.
APOE4, a major Alzheimer's disease risk gene, compromises bone quality in women through disruption of osteocytes—the long-lived cells responsible for maintaining bone microarchitecture—despite normal appearance on standard imaging. This finding suggests bone deterioration may serve as an early, detectable signal of neurodegenerative risk before cognitive symptoms emerge.
APOE4 carriers exhibit elevated neuronal excitability in specific hippocampal regions during youth, before cognitive symptoms manifest, with early excitability patterns predictive of later cognitive decline. This mechanism resembles accelerated aging and offers a window for intervention before irreversible neurodegeneration.
Roche has obtained CE mark approval for a blood test that identifies ApoE4 carriers, a genetic variant associated with increased Alzheimer's risk. This test streamlines risk stratification and treatment planning by enabling clinicians to prioritize patients for further evaluation and guide therapeutic decisions, particularly regarding amyloid-targeting therapies that carry differential risk profiles based on ApoE4 status.
Scribe Therapeutics and Eli Lilly have achieved a second milestone in developing in vivo CRISPR-based therapies for neurological and neuromuscular diseases. This advances the practical application of gene editing directly within the body, potentially enabling durable treatments delivered once or rarely, rather than requiring repeated interventions over a patient's lifetime.
Unlimited Bio has initiated a Phase 1/2a clinical trial combining AAV9-Follistatin and VEGF plasmid gene therapy to address age-related muscle loss and vascular insufficiency. The dual approach targets both muscle growth capacity and the circulatory support system that sustains muscle function—a systems-level intervention designed to address interconnected aspects of aging.
37 topics
13 topics
19 topics
23 topics
23 topics
15 topics
12 topics
21 topics
16 topics
18 topics
25 topics
17 topics
56 topics
33 topics
26 topics
24 topics
74 topics
49 topics
62 topics
23 topics
